What Happened
Viking Therapeutics posted strong Phase results for VK2735, its dual GLP-1/GIP agonist obesity drug, sending the stock up 35.67% in one of the biggest single-day moves in biotech this year. The print put VKTX back near its 2026 highs and reignited the broader GLP-1 weight loss drug race as a market theme.
Eli Lilly and Novo Nordisk — the two giants currently dominating the GLP-1 market — both caught sympathy bids on the news, a sign that investors see the data as validating the entire category, not just Viking.
What VK2735 Is
VK2735 is a dual agonist of the GLP-1 and GIP receptors — the same two pathways targeted by tirzepatide (Eli Lilly's Mounjaro/Zepbound). Viking's drug showed up to 14.7% mean body weight reduction after 13 weeks in subcutaneous Phase 2 studies, with no plateau observed. An oral formulation showed up to 12.2% weight loss at 13 weeks.
What makes VK2735 particularly interesting to analysts: Viking claims superior pharmacokinetics and up to 40% greater weight loss in primate models compared to tirzepatide. Human data will be the real test, but those numbers generated serious attention on Wall Street.
The global obesity drug market is projected to exceed $100 billion annually by 2030. Novo Nordisk's Wegovy and Eli Lilly's Zepbound are currently splitting the market. A credible third entrant with strong efficacy data — like VK2735 — would capture significant market share and put pressure on the incumbents.
Where the Drug Is in Development
Viking's Phase 3 VANQUISH trials — which will enroll thousands of patients and provide the definitive efficacy and safety data — are fully enrolled. Results are expected in 2026-2027. The company also has an oral tablet formulation of VK2735 heading into Phase 3, which is significant: the obesity market desperately wants a pill alternative to weekly injections.
The Risk
Biotech is binary. Phase 2 data rarely tells the full story — Phase 3 trials have a way of disappointing even when Phase 2 looked promising. The 35.67% single-day move priced in a lot of optimism. If Phase 3 VANQUISH data underperforms expectations, the stock could give back much of those gains just as fast.
That said, Viking has $502 million in cash as of Q2 2026 — enough runway to fund operations into 2028. The financial position is solid even in a scenario where Phase 3 takes longer than expected.